Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  DNA PROBES-BASED DIAGNOSTICS
A Global Strategic Business Report

This report analyzes the worldwide markets for DNA Probes-based Diagnostics in Millions of US$. The specific end-use segments discussed are Infectious Diseases, Cancer Testing, Genetic Predisposition, Identity/Forensics, Molecular HLA (Human Leukocyte Antigen) Typing, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 65 companies including many key and niche players worldwide such as Abbott Laboratories, Affymetrix Inc., Becton Dickinson & Company, Beckman Coulter, Inc., bioMerieux, Celera Group, Gen-Probe Incorporated, Genzyme Corporation, Luminex Molecular Diagnostics, QIAGEN, Roche Diagnostics, and Siemens Healthcare Diagnostics, Inc., Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-3405  PAGES:    455
PRICE:    $3450  DATE:       October 2008
COMPANIES:  65  MARKET DATA TABLES:   139
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  DNA PROBES-BASED DIAGNOSTICS (Complete Report) Pages : 455   | $3450
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Infectious Diseases.....I-3
  
   Cancer.....I-4
Genetic Predisposition.....I-4
Identity/Forensics.....I-4
Molecular HLA Testing.....I-4
Other Diagnostic Applications.....I-4
  
II. EXECUTIVE SUMMARY77$1950
  1. Market Dynamics.....II-18 $600  
   Industry Overview.....II-1
DNA Probes: Robust Growth Ahead.....II-1
Decoding the Genetic Puzzle.....II-1
1$100
   Advantages of DNA-Probe Tests.....II-2
Growth Drivers in a Nutshell.....II-2
Growth Inhibitors in a Nutshell.....II-2
1$100
   Genetic Profiling of Pathogens: A Road Less Traveled.....II-3
Roche’s Entry into the Hall of Molecular Fame.....II-3
DNA Technology: An Evolutionary Scan.....II-3
1$100
   An Era of Excellence: Tracking Landmark Breakthroughs in DNA Diagnostics.....II-41$100
   Opportunities.....II-5
Market Trends/Issues.....II-5
DNA Tests: Finding Use in Numerous Applications.....II-5
1$100
   World’s Aging Population Drives the Popularity of DNA-Probe Tests.....II-6
Reimbursements: “Under the Umbrella”.....II-6
Evolution of New & Virulent Infectious Agents.....II-6
The Enlightened Consumer of the 21st Century.....II-6
1$100
   Challenges In Widespread Deployment of DNA Based Diagnostics.....II-7
Miniaturization: An Uphill Task.....II-7
Improvements in Assay Capabilities.....II-7
1$100
   Information Handling & Processing: The Soft Side of Diagnostics.....II-8
Integration: The Ultimate Challenge.....II-8
United States: Unraveling the Country’s Edge in DNA based Diagnostics.....II-8
1$100
  2. DNA Probes-Based Diagnostics - A Primer.....II-96 $400  
   Diagnostic Gene Detection Products.....II-9
Molecular Diagnostics: A Powerful Disease Detection Tool.....II-9
1$100
   DNA Probes-Based Products.....II-10
Direct Detection of Target Sequence.....II-10
Nucleic Acid Amplification.....II-10
Gene Detection Using DNA Chips.....II-10
Gene Detection by DNA Sequencing.....II-10
1$100
   The Dynamics of Key Enabling Technologies.....II-11
In Situ Hybridization.....II-11
PCR: Polymerase Chain Reaction.....II-11
Chemiluminescence.....II-11
1$100
   Gen-Probe Tigris.....II-12
DNA Chips.....II-12
Key Players.....II-12
Players in Molecular Diagnostics Market.....II-12
Molecular Diagnostics - A Primer.....II-12
1$100
   Implications for Clinical Diagnostics.....II-13
Need of the Hour.....II-13
Molecular Diagnostics: Marking the Convergence of Numerous Technologies.....II-13
Impact of the Human Genome Project.....II-13
1$100
   Molecular Diagnostics: Domain of the Developed Countries.....II-14
“Tailored Patient Management”: An Epitomized Future of Molecular
  Diagnostics.....II-14
Futuristics: A Rumination.....II-14
1$100
  3. Product Overview.....II-159 $600  
   Background.....II-15
Gene Probe Technology.....II-15
What is DNA?.....II-15
DNA Probes.....II-15
1$100
   Miniaturization: A Revolutionary Method in DNA Analysis.....II-16
Gene Chip Technology.....II-16
DNA Chips.....II-16
Chromosome Painting Probes.....II-16
Diagnostic Applications Based on DNA Probes: An Overview.....II-16
Infectious Diseases.....II-16
1$100
   Respiratory Tract Infections.....II-17
Diagnosis of Mycoplasma.....II-17
DNA Probes to Detect Legionella Pneumophila.....II-17
Detecting Tuberculosis Through Rapid Diagnostic Tests.....II-17
How the Technique Works.....II-17
1$100
   Limitations.....II-18
Sexually Transmitted Diseases (STDs).....II-18
HIV.....II-18
HTLV-1 Testing.....II-18
Hepatitis Testing.....II-18
Chlamydia DNA Probes.....II-18
Detection of Intestinal Parasites.....II-18
Entamoeba Histolytica.....II-18
1$100
   Salmonella.....II-19
Identity/Forensics.....II-19
DNA Profiling: A Key Forensic Tool.....II-19
DNA-Based Forensic Diagnostics.....II-19
1$100
   Tracing Human Origins.....II-20
Genetic Predisposition.....II-20
Molecular HLA Testing.....II-20
Human Leukocyte Antigen (HLA) Typing.....II-20
Cancer Testing.....II-20
Cancer: A Deadly Disease Afflicting Millions.....II-20
Slow Detoxifiers: Potential Cancer Candidates.....II-20
1$100
   Improving Cancer Surgery Through Diagnostic Tests.....II-21
Types of Cancer.....II-21
Chronic Lymphocytic Leukemia (CLL).....II-21
Breast Cancer.....II-21
PCR Screening Technology for Breast Cancer.....II-21
Eye Cancers.....II-21
DNA Probes to Detect Retinoblastoma.....II-21
1$100
   Others.....II-22
The Ames test.....II-22
Genetic Testing.....II-22
Other Diagnostic Applications.....II-22
1$100
   Cystic Fibrosis.....II-23
Malaria Testing.....II-23
Detection of Multidrug Resistance.....II-23
Bacterial Resistance to Antibiotics.....II-23
DNA Probes for Agriculture.....II-23
1$100
  4. Product Innovations/Introductions.....II-248 $600  
   Luminex Molecular Introduces New xTAG™ Respiratory Viral Panel.....II-24
Gen-Probe Introduces Aptima HPV Assay in Europe.....II-24
Genzyme Genetics Introduces Prenatal Diagnosis and Carrier Testing.....II-24
1$100
   Affymetrix Launches New Cytogenetic Solution.....II-25
Genekam Biotech Develops New Commercial DNA-Test to Detect Bird Flu.....II-25
Seegene Launches Innovative DNA Test to Detect HPVs.....II-25
1$100
   deCODE Introduces deCODE T2.....II-26
InterGenetics Introduces OncoVue.....II-26
bioMérieux Unveils VIDAS C.....II-26
bioMérieux Unveils NucliSENS EasyQ HPV.....II-26
1$100
   Applied Biosystems Launches SOLiD System.....II-27
bioMérieux Introduces VIDAS® NT-proBNP.....II-27
Abbott Molecular Rolls Out Six DNA Probes.....II-27
1$100
   PerkinElmer Launches Two New Multiplexing Platforms for Genomic Research.....II-28
Kreatech Introduces First Complete Whole Genome Amplification Kit.....II-28
1$100
   Relative Genetics Introduces DNA Testing Services.....II-29
Sorenson Launches Over-the-counter Paternity Test Kits.....II-29
Kimball Genetics Introduces Warfarin Sensitivity DNA Test.....II-29
bioMérieux Introduces TEMPO EB.....II-29
1$100
   Gen-Probe Launches PCA3 Assay.....II-30
Genzyme Launches New KRAS Mutation Analysis.....II-30
BD Launches New BD Viper™ System for Automating Molecular Diagnostic Testing
  Process.....II-30
Affymetrix Unveils New GeneChip® Scanner with Higher Capacity Scanning.....II-30
1$100
   Genzyme Introduces EGFR Mutation Assay for Detecting Mutations.....II-31
bioMérieux Rolls Out FoodExpert-ID Molecular Multi-Detection Test for Feed
  Analysis.....II-31
1$100
  5. Recent Industry Activity.....II-3222 $1400  
   Genzyme Enters into Licensing Agreement with Moffitt Cancer Center.....II-32
Xceed Molecular Offers Gen-Probe License for Flow-Thru Chip® Technology.....II-32
Dako Denmark’s TOP2A FISH pharmDx Receives FDA Approval.....II-32
Roche Diagnostics Receives Approval for Elecsys Anti-HCV Assay.....II-32
1$100
   bioMérieux and FIND Ink Memorandum of Understanding.....II-33
BD Establishes Second Production Facility in China.....II-33
Shanghai Kehua Bio-engineering and bioMérieux Establish Joint Venture.....II-33
1$100
   Quidel to Enter into Alliance with bioMérieux.....II-34
Beckman Coulter Bags Rights to Hepatitis C Virus Test from Siemens.....II-34
Affymetrix Enters into Partnership with Pathwork Diagnostics.....II-34
1$100
   Luminex Signs Distribution and Sales Agreement with Abbott.....II-35
Gen-Probe to Acquire Innogenetics.....II-35
1$100
   Biocept to Introduce I.D.Rh(D).....II-36
DNA Testing Systems and DNAPrint Genomics Sign Sales Agreement.....II-36
Siemens Acquires Dade Behring.....II-36
1$100
   Sorenson Genomics Acquires Identigene.....II-37
BioServe Takes Over Genomics Collaborative.....II-37
Illumina Acquires Solexa.....II-37
1$100
   QIAGEN to Merge With eGene.....II-38
NorDiag Acquires Genpoint.....II-38
Cepheid Takes Over Sangtec Molecular Diagnostics.....II-38
3M Enters into Collaboration with Gen-Probe.....II-38
1$100
   Luminex Corporation Completes Acquisition of Tm Bioscience.....II-39
Ventana Medical Systems and C-Path to Collaborate with NCI and FDA.....II-39
1$100
   Ipsen and bioMérieux Enter into Theragnostics Agreement.....II-40
Celera Acquires Atria Genetics.....II-40
1$100
   Celera Acquires Berkeley HeartLab.....II-41
Beckman Coulter Enters into Partnership.....II-41
Affymetrix Partners with IPSOGEN for In-Vitro Diagnostic Cancer Testing.....II-41
1$100
   Ventana Medical Systems Collaborates with Genentech.....II-42
Siemens Medical Solutions Acquires Bayer’s Diagnostic Division.....II-42
Orchid Cellmark Acquires ReliaGene Technologies.....II-42
GATC Enters into Collaboration for Developing DNA-based Diagnostic Test.....II-42
1$100
   Genetic Solutions and Catapult Merge to Establish Catapult Genetics.....II-43
Grant Life Sciences Signs MoU with Alphagenics Diaco Biotechnologies.....II-43
1$100
   Gen-Probe and Millipore Ink Agreement to Market MTC-NI Test.....II-44
QIAGEN Acquires Digene Corporation.....II-44
1$100
   BD Diagnostics and Quest Diagnostics Sign Agreement for BD Viper™ System.....II-45
Enzo Biochem Plans to Produce Single Copy DNA Probes.....II-45
Affymetrix Signs Two Agreements with Sysmex.....II-45
1$100
   Affymetrix and Partners HealthCare Enter into Collaboration.....II-46
Affymetrix and Epigenomics Enter into an Agreement.....II-46
1$100
   Roche Introduces Elecsys TORCH Assays.....II-47
QIAGEN to Take Over Gentra.....II-47
LGC Acquires AGOWA to Extend German Operations.....II-47
ENZ Receives Patent for Phosphate Labeling for Medical Research & DNA Diagnostic
  Products.....II-47
1$100
   TMC Achieves CE Mark for its Tag-It Cystic Fibrosis Test Kit.....II-48
Toshiba Licenses Electrochemical Detection Technology to Antara.....II-48
Affymetrix Licenses Multiple Patents to Invitrogen.....II-48
1$100
   Abbott Enters into Agreement with ALSI for Licensing ProGRP Biomarker.....II-49
QIAGEN in Protein Crystallography Co-Marketing Agreement with ActiveSight.....II-49
Warnex Acquires Pro-DNA Diagnostic.....II-49
1$100
   Celera Genomics Gains Complete Ownership of Celera Diagnostics.....II-50
Gen-Probe Licenses Exclusive Rights for Diagnostic Tests Development from University of
  Michigan.....II-50
QIAGEN Enters into Licensing Agreement with Applied Biosystems for Real-Time PCR
  Technologies.....II-50
1$100
   IGC Collaborates with Roche for Cancer Biomarker Discovery.....II-51
Affymetrix Acquires ParAllele BioScience.....II-51
QIAGEN Enters into Distribution Agreement with Osmetech Molecular Diagnostics.....II-51
GlaxoSmithKline Acquires Canada-Based ID Biomedical Corp......II-51
1$100
   Gen-Probe Obtains FDA Approval for APTIMA.....II-52
Gen-Probe Signs Purchasing Agreement with Roche.....II-52
MP Biomedicals Acquires Qbiogene.....II-52
Roche Diagnostics Receives FDA Approval for AmpliChip CYP450 Test.....II-52
Ventana Launches ISH Tests.....II-52
Abbott Receives FDA Approval for Use of AutoVysion™ System.....II-52
1$100
   Affymetrix Opts Veridex for its GeneChip® Technology.....II-53
Abbott Signs Distribution Agreement with BioGenex.....II-53
1$100
  6. Focus on Select Players.....II-543 $300  
   Abbott Laboratories (US).....II-54
Affymetrix Inc (US).....II-54
Becton Dickinson & Company (US).....II-54
1$100
   Beckman Coulter, Inc. (US).....II-55
bioMérieux (France).....II-55
Celera Group (US).....II-55
Gen-Probe Incorporated (US).....II-55
1$100
   Genzyme Corporation (US).....II-56
Luminex Molecular Diagnostics (Canada).....II-56
QIAGEN (US).....II-56
Roche Diagnostics (Switzerland).....II-56
Siemens Healthcare Diagnostics, Inc. (US).....II-56
1$100
  7. Global Market Perspective.....II-57   
   Table 1: World Recent Past Current & Future Analysis for DNA Probes-based Diagnostics by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-571$350
   Table 2: World Long-term Projections for DNA Probes-based Diagnostics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-581$350
   Table 3: World 10-Year Perspective for DNA Probes-based Diagnostics by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-591$350
   Table 4: World Recent Past Current & Future Analysis for DNA Probes-based Diagnostics (Infectious Disease Diagnosis) by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-601$350
   Table 5: World Long-term Projections for DNA Probes-based Diagnostics (Infectious Disease Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-611$350
   Table 6: World 10-Year Perspective for DNA Probes-based Diagnostics (Infectious Disease Diagnosis) by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-621$350
   Table 7: World Recent Past Current & Future Analysis for DNA Probes-based Diagnostics (Cancer Diagnosis) by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-631$350
   Table 8: World Long-term Projections for DNA Probes-based Diagnostics (Cancer Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-641$350
   Table 9: World 10-Year Perspective for DNA Probes-based Diagnostics (Cancer Diagnosis) by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-651$350
   Table 10: World Recent Past Current & Future Analysis for DNA Probes-based Diagnostics (Genetic Predisposition Diagnosis) by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-661$350
   Table 11: World Long-term Projections for DNA Probes- based Diagnostics (Genetic Predisposition Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-671$350
   Table 12: World 10-Year Perspective for DNA Probes - based Diagnostics (Genetic Predisposition Diagnosis) by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-681$350
   Table 13: World Recent Past Current & Future Analysis for DNA Probes-based Diagnostics (Identity/Forensics Diagnosis) by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-691$350
   Table 14: World Long-term Projections for DNA Probes - based Diagnostics (Identity/Forensics Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-701$350
   Table 15: World 10-Year Perspective for DNA Probes-based Diagnostics (Identity/Forensics Diagnosis) by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-711$350
   Table 16: World Recent Past Current & Future Analysis for DNA Probes-based Diagnostics (Molecular HLA Testing) by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-721$350
   Table 17: World Long-term Projections for DNA Probes-based Diagnostics (Molecular HLA Testing) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-731$350
   Table 18: World 10-Year Perspective for DNA Probes-based Diagnostics (Molecular HLA) by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-741$350
   Table 19: World Recent Past Current & Future Analysis for DNA Probes-based Diagnostics in Other Types of Diagnosis by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-751$350
   Table 20: World Long-term Projections for DNA Probes - based Diagnostics in Other Types of Diagnosis by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-761$350
   Table 21: World 10-Year Perspective for DNA Probes- based Diagnostics in Other Types of Diagnosis by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan) and Latin America for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-771$350
III. MARKET73$1650
  1. The United States.....III-125 $1275  
   A. Market Analysis.....III-1
Outlook.....III-1
DNA-Based Diagnostic and Test Market: Progress Towards a New Phase.....III-1
Rise of DNA-Based Home Testing Kits Market.....III-1
1$75
   Product Launches.....III-23$225
   Strategic Corporate Developments.....III-515$675
   Key Players.....III-203$225
   B. Market Analytics.....III-23
Table 22: US Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-23
1$200
   Table 23: US Long-term Projections for DNA Probes - based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity / Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-241$200
   Table 24: US 10-Year Perspective for DNA Probes-based Diagnostics by Application Area Percentage Breakdown of Dollar Sales for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-25
1$200
  2. Canada.....III-265 $625  
   A. Market Analysis.....III-26
Outlook.....III-26
Key Player.....III-26
Product Launch.....III-26
Strategic Corporate Developments.....III-26
2$150
   B. Market Analytics.....III-28
Table 25: Canadian Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-28
1$200
   Table 26: Canadian Long-term Projections for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/ Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-291$200
   Table 27: Canadian 10-Year Perspective for DNA Probes-based Diagnostics by Application Area Percentage Breakdown of Dollar Sales for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-30
1$200
  3. Japan.....III-314 $525  
   A. Market Analysis.....III-31
Outlook.....III-31
Strategic Corporate Development.....III-31
1$75
   B. Market Analytics.....III-32
Table 28: Japanese Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-32
1$200
   Table 29: Japanese Long-term Projections for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/ Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-331$200
   Table 30: Japanese 10-Year Perspective for DNA Probes-based Diagnostics by Application Area Percentage Breakdown of Dollar Sales for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-34
1$200
  4. Europe.....III-357 $875  
   A. Market Analysis.....III-35
Outlook.....III-35
Product Launches.....III-35
1$75
   Strategic Corporate Developments.....III-36
B. Market Analytics.....III-36
Table 31: European Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-36
1$200
   Table 32: European Long-term Projections for DNA Probes-based Diagnostics by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-371$200
   Table 33: European 10-Year Perspective for DNA Probes-based Diagnostics by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-381$200
   Table 34: European Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-391$200
   Table 35: European Long-term Projections for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/ Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-401$200
   Table 36: European 10-Year Perspective for DNA Probes-based Diagnostics by Application Area Percentage Breakdown of Dollar Sales for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-41
1$200
  4a. France.....III-426 $650  
   A. Market Analysis.....III-42
Outlook.....III-42
Key Player.....III-42
Product Launches.....III-42
1$75
   Strategic Corporate Developments.....III-432$150
   B. Market Analytics.....III-45
Table 37: French Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-45
1$200
   Table 38: French Long-term Projections for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-461$200
   Table 39: French 10-Year Perspective for DNA Probes-based Diagnostics by Application Area Percentage Breakdown of Dollar Sales for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-47
1$200
  4b. Germany.....III-484 $500  
   A. Market Analysis.....III-48
Outlook.....III-48
Product Launch.....III-48
Strategic Corporate Developments.....III-48
1$75
   B. Market Analytics.....III-49
Table 40: German Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-49
1$200
   Table 41: German Long-term Projections for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/ Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-501$200
   Table 42: German 10-Year Perspective for DNA Probes-based Diagnostics by Application Area Percentage Breakdown of Dollar Sales for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-51
1$200
  4c. Italy.....III-524 $525  
   A. Market Analysis.....III-52
Strategic Corporate Development.....III-52
1$75
   B. Market Analytics.....III-53
Table 43: Italian Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area - Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-53
1$200
   Table 44: Italian Long-term Projections for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity / Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-541$200
   Table 45: Italian 10-Year Perspective for DNA Probes-based Diagnostics by Application Area- Percentage Breakdown of Dollar Sales for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-55
1$200
  4d. The United Kingdom.....III-564 $525  
   A. Market Analysis.....III-56
Outlook.....III-56
Strategic Corporate Development.....III-56
1$75
   B. Market Analytics.....III-57
Table 46: UK Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-57
1$200
   Table 47: UK Long-term Projections for DNA Probes - based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-581$200
   Table 48: UK 10-Year Perspective for DNA Probes- based Diagnostics by Application Area- Percentage Breakdown of Dollar Sales for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-59
1$200
  4e. Rest of Europe.....III-606 $650  
   A. Market Analysis.....III-60
Outlook.....III-60
Product Launches.....III-60
1$75
   Strategic Corporate Developments.....III-611$75
   Key Player.....III-621$75
   B. Market Analytics.....III-63
Table 49: Rest of Europe Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area - Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-63
1$200
   Table 50: Rest of Europe Long-term Projections for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-641$200
   Table 51: Rest of Europe 10-Year Perspective for DNA Probes-based Diagnostics by Application Area- Percentage Breakdown of Dollar Sales for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-65
1$200
  5. Asia-Pacific.....III-665 $575  
   A. Market Analysis.....III-66
Outlook.....III-66
Strategic Corporate Development.....III-66
2$150
   B. Market Analytics.....III-68
Table 52: Asia-Pacific Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-68
1$200
   Table 53: Asia-Pacific Long-term Projections for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-691$200
   Table 54: Asia-Pacific 10-Year Perspective for DNA Probes-based Diagnostics by Application Area- Percentage Breakdown of Dollar Sales for Infectious Diseases, Cancer, Genetic Predisposition, dentity/ Forensics, Molecular HLA Testing, and Others Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-70
1$200
  6. Latin America.....III-713 $600  
   Market Analysis.....III-71
Table 55: Latin American Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-71
1$200
   Table 56: Latin America Long-term Projections for DNA Probes-based Diagnostics by Application Area- Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-721$200
   Table 57: Latin American 10-Year Perspective for DNA Probes-based Diagnostics by Application Area- Percentage Breakdown of Dollar Sales for Infectious Diseases, Cancer, Genetic Predisposition, dentity/ Forensics, Molecular HLA Testing, and Others Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-731$200
IV. COMPETITIVE LANDSCAPE 289$995
  
Total Companies Profiled: 65 (including Divisions/Subsidiaries - 80 )

Region/Country                 Players


The United States                  53
Canada                              6
Japan                               2
Europe                             17
     France                         1
     Germany                        7
     The United Kingdom             3
     Italy                          1
     Rest of Europe                 5
Asia-Pacific (Excluding Japan)      2
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.